{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:06:32Z","timestamp":1777334792963,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017596","name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte","doi-asserted-by":"publisher","award":["V-2020.2\/68502\/2020-2024"],"award-info":[{"award-number":["V-2020.2\/68502\/2020-2024"]}],"id":[{"id":"10.13039\/100017596","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Hospital Bonn","award":["V-2020.2\/68502\/2020-2024"],"award-info":[{"award-number":["V-2020.2\/68502\/2020-2024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40268-024-00499-x","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T03:46:29Z","timestamp":1737431189000},"page":"35-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analyses of Adverse Drug Reactions to Fluoroquinolones in Spontaneous Reports Before and After the Referral and in Clinical Routine Cases"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-051X","authenticated-orcid":false,"given":"Diana","family":"Dubrall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-6239","authenticated-orcid":false,"given":"Julia","family":"Wicherski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Below","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"G\u00f6rtzen-Patin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0788-0317","authenticated-orcid":false,"given":"Matthias","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-0725","authenticated-orcid":false,"given":"Sven","family":"Zenker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-6058","authenticated-orcid":false,"given":"Britta","family":"Haenisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-0891","authenticated-orcid":false,"given":"Bernhardt","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"10","key":"499_CR1","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1039\/C9MD00120D","volume":"10","author":"TDM Pham","year":"2019","unstructured":"Pham TDM, Ziora ZM, Blaskovich MAT. Quinolone antibiotics. Medchemcomm. 2019;10(10):1719\u201339.","journal-title":"Medchemcomm."},{"issue":"7662","key":"499_CR2","first-page":"135","volume":"337","author":"JH Tanne","year":"2008","unstructured":"Tanne JH. FDA adds \u201cblack box\u201d warning label to fluoroquinolone antibiotics. BMJ. 2008;337(7662):135.","journal-title":"BMJ"},{"key":"499_CR3","unstructured":"US Food and Drug Administration (FDA). FDA updates warnings for fluoroquinolone antibiotics. Limits use for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated urinary tract infections, 2016. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-updates-warnings-fluoroquinolone-antibiotics. Accessed 15 Nov 2024."},{"key":"499_CR4","unstructured":"US Food and Drug Administration (FDA). Fluoroquinolone Antimicrobial Drugs Information. https:\/\/www.fda.gov\/drugs\/information-drug-class\/fluoroquinolone-antimicrobial-drugs-information. Accessed 15 Nov 2024."},{"key":"499_CR5","unstructured":"US Food and Drug Administration (FDA). FDA In Brief: FDA warns that fluoroquinolone antibiotics can cause aortic aneurysm in certain patients. https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-warns-fluoroquinolone-antibiotics-can-cause-aortic-aneurysm-certain-patients. Accessed 15 Nov 2024."},{"key":"499_CR6","unstructured":"European Medicines Agency (EMA). Quofenix \/ Quinsair\u2014direct healthcare professional communication (DHPC). https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/quofenix-quinsair. Accessed 15 Nov 2024."},{"key":"499_CR7","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft. Rote-Hand-Brief. https:\/\/www.akdae.de\/fileadmin\/user_upload\/akdae\/Arzneimittelsicherheit\/RHB\/Archiv\/2019\/20190408.pdf. Accessed 15 Nov 2024."},{"key":"499_CR8","unstructured":"Federal Institute for Drugs and Medical Devices. Fluorchinolone: Schwere und langanhaltende Nebenwirkungen im Bereich Muskeln, Gelenke und Nervensystem. https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RV_STP\/a-f\/fluorchinolone-bewegungsapparat.html. Accessed 15 Nov 2024."},{"key":"499_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40264-018-0751-2","volume":"42","author":"E Gorelik","year":"2019","unstructured":"Gorelik E, Masarwa R, Perlman A, et al. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf. 2019;42:529\u201338.","journal-title":"Drug Saf"},{"key":"499_CR10","unstructured":"Krahn A. Zur toxikologie der antibiotikagruppe der gyrasehemmer\/chinolone unter besonderer ber\u00fccksichtigung der fluorchinolone."},{"key":"499_CR11","unstructured":"European Medicines Agency (EMA). Quinolone- and fluoroquinolone-containing medicinal products\u2014referral. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/quinolone-and-fluoroquinolone-containing-medicinal-products. Accessed 15 Nov 2024."},{"key":"499_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.18773\/austprescr.2021.035","volume":"44","author":"D Baggio","year":"2021","unstructured":"Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr. 2021;44:161\u20134.","journal-title":"Aust Prescr"},{"key":"499_CR13","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00228-019-02713-1","volume":"75","author":"C Alves","year":"2019","unstructured":"Alves C, Mendes D, Marques FB. Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2019;75:1431\u201343.","journal-title":"Eur J Clin Pharmacol"},{"key":"499_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034844","volume":"10","author":"S Baik","year":"2020","unstructured":"Baik S, Lau J, Huser V, et al. Association between tendon ruptures and use of fluoroquinolone, and other oral antibiotics: a 10-year retrospective study of 1 million US senior Medicare beneficiaries. BMJ Open. 2020;10: e034844.","journal-title":"BMJ Open"},{"issue":"11","key":"499_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/pds.1214","volume":"15","author":"JD Seeger","year":"2006","unstructured":"Seeger JD, West WA, Fife D, et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf. 2006;15(11):784\u201392.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"499_CR16","unstructured":"Federal Institute for Drugs and Medical Devices. Pharmacoepidemiology - Serious Adverse Drug Reactions of Fluoroquinolones: pharmacoepidemiological analyses. https:\/\/www.bfarm.de\/EN\/BfArM\/Tasks\/Research\/Pharmacoepidemiology\/_node.html. Accessed 15 Nov 2024."},{"key":"499_CR17","unstructured":"European Medicines Ageny (EMA). Guideline on good pharmacovigilance practices (GVP) Module VI\u2014collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). 2017. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf.11. Accessed 15 Nov 2024."},{"key":"499_CR18","unstructured":"European Medicines Agency (EMA). Guideline on good phar-macovigilance practices (GVP) Annex I\u2014definitions (Rev 4). 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf. Accessed 15 Nov 2024."},{"issue":"23","key":"499_CR19","first-page":"393","volume":"115","author":"D Dubrall","year":"2018","unstructured":"Dubrall D, Schmid M, Alesik E, et al. Frequent adverse drug reactions, and medication groups under suspicion. Dtsch Arztebl Int. 2018;115(23):393\u2013440.","journal-title":"Dtsch Arztebl Int"},{"key":"499_CR20","unstructured":"European Medicines Agency. EudraVigilance. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance. Accessed 15 Nov 2024."},{"key":"499_CR21","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). https:\/\/www.meddra.org\/. Accessed 15 Nov 2024."},{"key":"499_CR22","unstructured":"European Medicines Agency. Medicinal product dictionary. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/data-medicines-iso-idmp-standards\/extended-eudravigilance-medicinal-product-dictionary-xevmpd-training. Accessed 15 Nov 2024."},{"key":"499_CR23","unstructured":"Federal Institute for Drugs and Medical Devices. ATC code. https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Kodiersysteme\/ATC\/atc-ddd-amtlich-2023.pdf?__blob=publicationFile. Accessed 15 Nov 2024."},{"issue":"7","key":"499_CR24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2165\/00002018-200831070-00006","volume":"31","author":"D Motola","year":"2008","unstructured":"Motola D, Vargiu A, Leone R, et al. Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. Drug Saf. 2008;31(7):609\u201316.","journal-title":"Drug Saf"},{"key":"499_CR25","unstructured":"Central Research Institute for Ambulatory Health Care in Germany. https:\/\/www.zi.de\/. Accessed 15 Nov 2024."},{"key":"499_CR26","doi-asserted-by":"crossref","unstructured":"Semler SC, Wissing F, Heyder R. German medical informatics initiative. Methods Inf Med. 2018;57(S 01):e50\u20136.","DOI":"10.3414\/ME18-03-0003"},{"key":"499_CR27","doi-asserted-by":"crossref","unstructured":"Winter A, St\u00e4ubert S, Ammon D, Aiche S, Beyan O, Bischoff V et al. Smart medical information technology for healthcare (SMITH). Methods Inf Med. 2018;57(S 01):e92\u2013105.","DOI":"10.3414\/ME18-02-0004"},{"key":"499_CR28","unstructured":"Federal Institute for Drugs and Medical Devices. ICD-10_GM. https:\/\/www.bfarm.de\/EN\/Code-systems\/Classifications\/ICD\/ICD-10-GM\/_node.html. Accessed 15 Nov 2024."},{"key":"499_CR29","unstructured":"European Medicines Agency. Annual Report 2022. https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/2022-annual-report-european-medicines-agency_en.pdf. Accessed 15 Nov 2024."},{"key":"499_CR30","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40264-023-01355-8","volume":"46","author":"P Christ","year":"2023","unstructured":"Christ P, Dubrall D, Schmid M, Sachs B. Comparative analysis of information provided in German adverse drug reaction reports sent by physicians, pharmacists and consumers. Drug Saf. 2023;46:1363\u201379.","journal-title":"Drug Saf"},{"key":"499_CR31","unstructured":"European Medicines Agency. Legal framework: pharmacovigilance. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/pharmacovigilance-overview\/legal-framework-pharmacovigilance. Accessed 15 Nov 2024."},{"key":"499_CR32","unstructured":"Kassen\u00e4rztliche Bundesvereinigung (KBV): RESIST. Antibiotika bewusst anwenden\u2014resistenzen vermeiden. http:\/\/www.kbv.de\/html\/resist.php. Accessed 15 Nov 2024."},{"key":"499_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1471-2296-13-124","volume":"13","author":"A Altiner","year":"2012","unstructured":"Altiner A, Berner R, Diener A, et al. Converting habits of antibiotic prescribing for respiratory tract infections in German primary care\u2014the cluster-randomized controlled CHANGE-2 trial. BMC Fam Pract. 2012;13:124.","journal-title":"BMC Fam Pract"},{"key":"499_CR34","unstructured":"Bundesamt f\u00fcr Verbraucherschutz und Lebensmittelsicherheit (BVL): GERMAP 2015. Antibiotika-Resistenz und -Verbrauch, Bericht \u00fcber den Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und Veterin\u00e4rmedizin in Deutschland. file:\/\/\/C:\/Users\/jholstiege\/Downloads\/germap2015.pdf"},{"key":"499_CR35","first-page":"679","volume":"117","author":"J Holstiege","year":"2020","unstructured":"Holstiege J, Schulz M, Akmatov M, et al. The decline in outpatient antibiotic use an analysis of Nationwide Prescription Data From 2010 to 2018. Dtsch Arztebl Int. 2020;117:679\u201386.","journal-title":"Dtsch Arztebl Int"},{"key":"499_CR36","unstructured":"Central Research Institute for Ambulatory Health Care in Germany. https:\/\/www.zi.de\/themen\/arznei-und-heilmittel\/verordnungsdaten\/rx-trendbericht\/wirkstoffgruppen. Accessed 15 Nov 2024."},{"key":"499_CR37","unstructured":"Schuster R, Emcke T,von Arnstedt E, et al. Antibiotic prescriptions before, during and after the corona pandemic in Schleswig-Holstein. 30. Jahrestagung der Gesellschaft f\u00fcr Arzneimittelanwendungsforschung und Arzneimittelepidemiologie (GAA)."},{"key":"499_CR38","unstructured":"PharMaAnalyst. https:\/\/arzneimittel.wido.de\/PharMaAnalyst\/;jsessionid=9EAC86F92D41F462382A7C34700FE9F9?0. Accessed 15 Nov 2024."},{"key":"499_CR39","unstructured":"European Medicines Agency. Study of impact of EU label changes for fluoroquinolone containing medicinal products for systemic and inhalation use\u2014post-referral prescribing trends. https:\/\/www.encepp.eu\/encepp\/openAttachment\/studyResult\/48007. Accessed 15 Nov 2024."},{"key":"499_CR40","unstructured":"European Medicines Agency. Fluoroquinolone antibiotics: reminder of measures to reduce the risk of long-lasting, disabling and potentially irreversible side effects. https:\/\/www.ema.europa.eu\/en\/news\/fluoroquinolone-antibiotics-reminder-measures-reduce-risk-long-lasting-disabling-potentially. Accessed 15 Nov 2024."},{"key":"499_CR41","doi-asserted-by":"publisher","first-page":"11073","DOI":"10.1038\/s41598-021-90692-8","volume":"11","author":"I Wee","year":"2021","unstructured":"Wee I, Chin B, Syn N, et al. The association between fluoroquinolones and aortic dissection and aortic aneurysms: a systematic review and meta-analysis. Sci Rep. 2021;11:11073.","journal-title":"Sci Rep"},{"issue":"11","key":"499_CR42","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/14740338.2019.1665022","volume":"18","author":"AC Bennett","year":"2019","unstructured":"Bennett AC, Bennett CL, Witherspoon BJ, Knopf KB. An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms\/dissections disseminated by the Food and Drug Administration and the European Medicines Agency. Expert Opin Drug Saf. 2019;18(11):1055\u201363.","journal-title":"Expert Opin Drug Saf"},{"key":"499_CR43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejim.2020.01.009","volume":"75","author":"M Gatti","year":"2020","unstructured":"Gatti M, Bianchin M, Raschi E. Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: an umbrella review. Eur J Internal Med. 2020;75:60\u201370.","journal-title":"Eur J Internal Med."},{"key":"499_CR44","unstructured":"European Medicines Agency. PRAC recommendations on signals. https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/prac-recommendations-signals-adopted-31-august-3-september-2020-prac-meeting_en.pdf. Accessed 15 Nov 2024."},{"issue":"13","key":"499_CR45","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2012.383","volume":"307","author":"M Etminan","year":"2012","unstructured":"Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012;307(13):1414\u20139.","journal-title":"JAMA"},{"issue":"09","key":"499_CR46","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/jac\/dku145","volume":"69","author":"CS Chui","year":"2014","unstructured":"Chui CS, Man KK, Cheng CL, et al. An investigation of the potential association between retinal detachment and oral fluoroquinolones: a self-controlled case series study. J Antimicrob Chemother. 2014;69(09):2563\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"499_CR47","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/pds.4873","volume":"28","author":"G Bonaldo","year":"2019","unstructured":"Bonaldo G, Andriani LA, D\u2019Annibali O, et al. Cardiovascular safety of macrolide and fluoroquinolone antibiotics: an analysis of the WHO database of adverse drug reactions. Pharmacoepidemiol Drug Saf. 2019;28:1457\u201363.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"04","key":"499_CR48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijantimicag.2006.11.011","volume":"29","author":"ME Falagas","year":"2007","unstructured":"Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents. 2007;29(04):374\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"499_CR49","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2165\/11536810-000000000-00000","volume":"33","author":"F Lapi","year":"2010","unstructured":"Lapi F, Tuccori M, Motola D, et al. Safety profile of the fluoroquinolones analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy. Drug Saf. 2010;33(9):789\u201399.","journal-title":"Drug Saf"},{"issue":"5","key":"499_CR50","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1089\/jwh.1998.7.547","volume":"7","author":"SM Ebert","year":"1998","unstructured":"Ebert SM, Liu XK, Woolsley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 1998;7(5):547\u201357.","journal-title":"J Womens Health"},{"key":"499_CR51","unstructured":"European Medicines Agency. Referral Avelox. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/avelox-article-6-12-referral-annex-i-ii-iii_en.pdf. Accessed 15 Nov 2024."},{"key":"499_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/ph15020143","volume":"15","author":"M Huruba","year":"2022","unstructured":"Huruba M, Farcas A, Leucuta DC, et al. A VigiBase descriptive study of fluoroquinolone-associated peripheral nervous system disorders. Pharmaceuticals. 2022;15:143.","journal-title":"Pharmaceuticals"},{"key":"499_CR53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jad.2020.03.082","volume":"271","author":"A Steffen","year":"2020","unstructured":"Steffen A, Thom J, Jakobi F, et al. Trends in prevalence of depression in Germany between 2009 and 2017 based on nationwide ambulatory claims data. J Affect Dis. 2020;271:239\u201347.","journal-title":"J Affect Dis"},{"issue":"10","key":"499_CR54","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/15622975.2021.2014152","volume":"24","author":"F Streit","year":"2023","unstructured":"Streit F, Zillich L, Frank J, et al. Lifetime and current depression in the German National Cohort (NAKO). World J Biol Psychiatry. 2023;24(10):865\u201380.","journal-title":"World J Biol Psychiatry."},{"key":"499_CR55","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","volume":"3","author":"L Colloca","year":"2017","unstructured":"Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"499_CR56","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/11587280-000000000-00000","volume":"34","author":"AM Tom\u00e9","year":"2011","unstructured":"Tom\u00e9 AM, Filipe A. Quinolones\u2014review of psychiatric and neurological adverse reactions. Drug Saf. 2011;34(6):465\u201388.","journal-title":"Drug Saf"},{"key":"499_CR57","unstructured":"European Medicines Agency. Assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/quinolone-and-fluoroquinolone-article-31-referral-assessment-report_en.pdf. Accessed 15 Nov 2024."},{"issue":"6","key":"499_CR58","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/phar.1761","volume":"36","author":"MR Bidell","year":"2016","unstructured":"Bidell MR, Lodise TP. Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk? Pharmacotherapy. 2016;36(6):679\u201393.","journal-title":"Pharmacotherapy"},{"key":"499_CR59","unstructured":"European Medicines Agency. Quinsair product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/quinsair-epar-product-information_en.pdf. Accessed 15 Nov 2024."},{"issue":"15","key":"499_CR60","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1001\/archinte.163.15.1801","volume":"163","author":"PD van der Linden","year":"2003","unstructured":"van der Linden PD, Sturkenboom MCJM, Herings RMC, et al. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med. 2003;163(15):1801\u20137.","journal-title":"Arch Intern Med"},{"key":"499_CR61","doi-asserted-by":"crossref","unstructured":"Nibell O, Svanstr\u00f6m H, Inghammer M. Oral Fluoroquinolone use and the risk of acute liver injury: a nationwide cohort study. CID; 74\/12:2152\u20132158.","DOI":"10.1093\/cid\/ciab825"},{"key":"499_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.994821","volume":"13","author":"T Hu","year":"2022","unstructured":"Hu T, Sun Y, An Z. Dose- and time-dependent manners of moxifloxacin induced liver injury by targeted metabolomics study. Front Pharmcol. 2022;13: 994821.","journal-title":"Front Pharmcol."},{"key":"499_CR63","doi-asserted-by":"crossref","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterol. 2015;148(7):1340\u20131352.","DOI":"10.1053\/j.gastro.2015.03.006"},{"issue":"5","key":"499_CR64","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"9","key":"499_CR65","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0895-4356(02)00450-X","volume":"55","author":"J Hasford","year":"2002","unstructured":"Hasford J, Goettler M, Munter KH, et al. Physicians\u2019 knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol. 2002;55(9):945\u201350.","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"499_CR66","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman KB, Demakas AR, Dimbil M, et al. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS). Drug Saf. 2014;37(11):971\u201380.","journal-title":"Drug Saf"},{"key":"499_CR67","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Nor\u00e9n GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37:65\u201377.","journal-title":"Drug Saf"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00499-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00499-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00499-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T03:14:27Z","timestamp":1745205267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00499-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["499"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00499-x","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"3 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ANKA is funded by own resources from the German Federal Institute for Drugs and Medical Devices\u2019 (BfArM) and the Institute for Medical Biometry, Informatics, and Epidemiology (IMBIE), University Hospital Bonn, Germany (V-2020.2\/68502\/2020-2024). The data provisioning services provided by the data integration center (DIC) Bonn were created with and\/or are currently supported, in part, via funding by the Federal Ministry of Education and Science (BMBF) under grant numbers (FKZ): 01ZZ1602C, 01ZZ1803Q, 01ZZ2303G, and 01KX2121.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DD and MS are supported by the ANKA project, which is founded by the Federal Institute for Drugs and Medical Devices and the Institute for Medical Biometry, Informatics and Epidemiology at the University Hospital Bonn.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The ethics committee of the Medical Faculty of Bonn waved the need for approval since this is not required for retrospective analyses based on pseudonymized spontaneous reports from EudraVigilance and clinical routine data from the University Hospital Bonn and stated that fthere are no ethical concerns (file no. 458\/20 and 100\/21). Thus, consent to participate is not required and was not obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The pseudonymized ADR reports from EudraVigilance are not publicly accessible due to data protection requirements. Distinct levels of access are provided for various stakeholders (). Being one of the competent authorities in Germany, the highest level of access is granted to the Federal Institute for Drugs and Medical Devices (BfArM). Nevertheless, even with the lowest access level, researchers can perform the same analysis in EudraVigilance (EV) with aggregated data (public access: ). For further information regarding processing personal data in the context of the operation of EudraVigilance Human we refer to the European Medicines Agency\u2019s Data Protection Notice for EudraVigilance Human.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"DD, JW, BH, and BS contributed to the conception and design of the study. DD selected the statistical methods, performed the analysis and created all tables and figures. The results were discussed by all authors. The first draft of the manuscript was written by DD. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author's contributions"}}]}}